Herrschaft, 2012, [21] [95]

Mild to moderate dementia associated with neuropsychiatric symptoms

Multicenter, double-blind, randomized, placebo- controlled

402 (200 in the treatment group and 202 in the placebo group)

>50 years (no upper limit; mean 65 ± 9)

240 mg EGb 761/ day (vs. placebo) for 24 weeks, no follow-up

Secondary outcome variable: change in 11-point box scales for the rating of presence and severity of dizziness and tinnitus from baseline.

Dizziness: Change from baseline at week 24 for the dizziness 11-point box scale was significant between groups (−0.6 for GBE vs. −0.2 for placebo; p < 0.001); mean reduction difference in dizziness severity in favor of GBE treated patients compared to placebo was statistically meaningful (−0.58 [95% CI: −0.90, −0.26])

Tinnitus: Change from baseline at week 24 for the tinnitus 11-point box scale was not significantly different between groups (−0.4 for GBE vs. −0.3 for placebo; p = 0.31); mean reduction difference in tinnitus severity in favor of GBE treated patients compared to placebo was statistically meaningful (−0.14 [95% CI: −0.50, −0.22]).

Ihl, 2011, [21] [93]

Mild to moderate dementia with neuropsychiatric symptoms

Multicenter, randomized, placebo- controlled

404 (202 in the treatment group and 202 in the placebo group); i.d.

>50 years (no upper limit)

240 mg EGb 761/ day (vs. placebo) for 24 weeks, no information on follow-up

Secondary outcome variable: change in 11-point box scales for the rating of presence and severity of dizziness and tinnitus from baseline.

Dizziness: Change from baseline at week 24 for the dizziness 11-point box scale was −0.8 for the GBE group and −0.3 for the placebo group; p < 0.001; mean reduction difference in dizziness severity in favor of GBE treated patients compared to placebo was statistically meaningful (−0.74 [95% CI: −1.02, −0.46])

Tinnitus: Change from baseline at week 24 for the tinnitus 11-point box scale was −0.5 for the GBE group and −0.1 for the placebo group; p < 0.001; mean reduction difference in tinnitus severity in favor of GBE treated patients compared to placebo was statistically meaningful (−0.97 [95% CI: −1.27, −0.67]).